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Abstract: Defective clearance mechanisms lead to the accumulation of amyloid-beta (Aβ) peptides
in the Alzheimer’s brain. Though predominantly generated in neurons, little is known about how
these hydrophobic, aggregation-prone, and tightly membrane-associated peptides exit into the
extracellular space where they deposit and propagate neurotoxicity. The ability for P-glycoprotein
(P-gp), an ATP-binding cassette (ABC) transporter, to export Aβ across the blood-brain barrier (BBB)
has previously been reported. However, controversies surrounding the P-gp–Aβ interaction persist.
Here, molecular data affirm that both Aβ40 and Aβ42 peptide isoforms directly interact with and
are substrates of P-gp. This was reinforced ex vivo by the inhibition of Aβ42 transport in brain
capillaries from P-gp-knockout mice. Moreover, we explored whether P-gp could exert the same role
in neurons. Comparison between non-neuronal CHO-APP and human neuroblastoma SK-N-SH cells
revealed that P-gp is expressed and active in both cell types. Inhibiting P-gp activity using verapamil
and nicardipine impaired Aβ40 and Aβ42 secretion from both cell types, as determined by ELISA.
Collectively, these findings implicate P-gp in Aβ export from neurons, as well as across the BBB
endothelium, and suggest that restoring or enhancing P-gp function could be a viable therapeutic
approach for removing excess Aβ out of the brain in Alzheimer’s disease.
Keywords: P-glycoprotein; ABCB1; amyloid-beta; neuron; SK-N-SH; Alzheimer’s disease
1. Introduction
The accumulation of amyloid-beta (Aβ) peptides in the brain is a key pathological
hallmark of Alzheimer’s disease (AD). These peptides vary between 37–43 amino acids
in length and exist in a range of conformations and assembly states, from monomers to
oligomers, protofibrils, and finally insoluble fibrils and plaques [1]. Aβ40 and the more
hydrophobic and aggregation-prone Aβ42 are the most common isoforms, with a higher
ratio of Aβ42: Aβ40 being associated with increased neurotoxicity, and accelerated disease
pathology and cognitive decline [2]. In the brain, these peptides are constitutively produced
in neurons and astrocytes following enzymatic cleavage of the transmembrane amyloid
precursor protein (APP), and subsequently rapidly cleared [3–5]. Studies in late-onset AD
patients have shown that the production rate of Aβ remains unaltered; rather, impaired
cellular clearance mechanisms are responsible for their accumulation in the brain [6]. Excess
levels of soluble oligomeric Aβ have been demonstrated to impair long-term potentiation,
drive synaptic and receptor dysfunction, propagate tau pathology, neuroinflammation,
and oxidative stress, and correlate with disease severity [7–9].
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Both intra- and extracellular Aβ accumulation have been implicated in neurotoxicity,
with the former reported to precede the latter [9–12]. This raises the question of how
intraneuronally-generated peptides are able to exit neurons and enter the extracellular
space. The hydrophobic, aggregation-prone and highly membrane-associated nature of the
Aβ peptide suggests that its constitutive release from cells relies on active transport [13,14].
P-glycoprotein (P-gp), also known as ATP-binding cassette (ABC) transporter B-family
subtype 1 (ABCB1) or multi-drug resistance protein 1 (MDR1), is an ATP-dependent
exporter protein with broad substrate specificity, that is ubiquitously expressed on cells
with barrier or excretory functions [15]. Several studies have provided evidence that
P-gp at the blood-brain barrier (BBB) is responsible for Aβ export out of the brain [16].
Consequently, we hypothesised that such a mechanism could also occur in the neuron.
However, there remains overall skepticism about the capacity of P-gp to carry these
peptides due to their considerably larger size than most known P-gp substrates [14,17].
The aim of the present study was two-fold: firstly, we sought to provide unequivocal
evidence that P-gp is able to transport Aβ peptides using in vitro and ex vivo model
systems that have been validated previously [18]. Secondly, we investigated the role of
neuronal P-gp, in a cell culture system utilised extensively in AD research, to ascertain
whether P-gp plays a role at the site of peptide generation and peptide-mediated damage.
2. Results
2.1. Biochemical Characterisation of the Interaction between Aβ40 and Aβ42 with P-gp
The baculovirus system provides high capacity expression of membrane proteins,
including human P-gp with full retention of function including substrate binding [19–21].
Figure 1a demonstrates that P-gp was purified to near homogeneity from High-Five
membranes and eluted specifically in the presence of 400 mM imidazole. The efficiency of
reconstitution was routinely assessed as described previously [21] and the concentration of
P-gp obtained in the present investigation was 0.092 ± 0.036 mg/mL (n = 4). The total yield
was 234 ± 86 µg of purified P-gp per 100 mg of crude High-Five membrane, indicating
that the expression was >0.2% of total membrane protein. These parameters are similar to
previously published values [21].
The tryptophan quenching assay has been widely used in the field to describe the
selectivity and apparent potency of ligand/substrate interaction with P-gp. The affinity is
classified as apparent since it measures the binding step and subsequent interaction with a
proximal tryptophan residue. Consequently, this assay was used to provide further evidence
to support a putative interaction between Aβ peptides and P-gp. A recent publication from
our group and collaborators using molecular docking [14] indicated that this interaction is
complex, and the kinetics are likely to be slow. Consequently, the assay conditions were
configured with an elevated temperature (37 ◦C) and a longer incubation time than typically
adopted for ligand binding studies [22]. As shown in Figure 1b,c, both peptides were able to
produce a dose-dependent quenching of the endogenous tryptophan fluorescence intensity,
with no shift in the maximal wavelength. The extent of reduction in signal was 20–40% of
that produced by the P-gp modulator nicardipine. Numerous researchers [19,23–25] have
demonstrated considerable variability in the extent of tryptophan quenching by drugs and
short peptide substrates of P-gp. These observations suggest that the Aβ peptides have a
direct interaction with P-gp that is similar to established drug substrates and inhibitors.
This is supported by an earlier study demonstrating that the Aβ peptides quench the
fluorescence of an extrinsic probe (MIANS) covalently attached to P-gp [26]. MIANS was
attached at the nucleotide-binding domains of P-gp and this indicates a long-distance
allosteric interaction, whereas the intrinsic tryptophan quenching is thought to involve
residues proximal to the drug binding site and central cavity [23].
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Figure 1. The interaction between Aβ40 and tides with purified, recons ituted P-gp. (a) Fractions obtained from
the metal ffinity purification of P-gp were separate - and detected with Instant BlueTM protein stain.
Fractions (40 µL) from each stage of the purification were loaded onto the gel. FT corresponds to the unbound detergent
extracted material, 20 mM and 60 mM represent washing stages, and 400 mM is the elution phase. (b) Representative
fluorescence emission spectra were obtained for the endogenous tryptophan residues of purified, reconstituted P-gp (15 µg)
with excitation at 295 ± 10 nm at 37 ◦C. Spectra were recorded in the absence or presence of a series of Aβ40 concentrations.
(c) Fluorescence emission spectra obtained as in (b), but with varying concentrations of Aβ42 peptide. (d) ATPase ac ivity
of purified, reconstituted P-gp (0.2–0.5 µg) in th presence of varyi g concentrations of nicardipine. The activity was
measured over 40 min at 37 ◦C and normalised to the value obtained in the absence of drug (basal). Data were fitted by the
general dose-response relationship using non-linear least squares regression and values represent mean ± SEM obtained
from four independent preparations. (e) ATPase activity of purified, reconstituted P-gp (0.2–0.5 µg) in the presence of
varying concentrations of Aβ40 and Aβ42 peptide. The activity was measured over 40 min at 37 ◦C and normalised to the
value obtained in the absence of drug (basal). Data were fitted by a hyperbolic relationship using non-linear least squares
regression and values represent mean ± SEM obtained from three independent preparations.
Binding to the transporter represents the first step in the process of translocation across
the membrane and therefore an activity assay was chosen to further explore the interaction
between Aβ peptides and P-gp. Transported substrates of P-gp increase the rate of ATP
hydrolysis [27–30], whereas pure inhibitors reduce the activity [31,32]. Consequently, mea-
suring substrate effects on ATPase activity provides a rigorous assessment of the interaction
with P-gp at the level of initial binding and the subsequent coupling event. Figure 1d shows
the dose-dependent stimulation of ATPase activity by nicardipine. The overall activity of
purified, reconstituted P-gp was characterised with a basal level of 419 ± 30 nmol/min/mg
and a maximal activity of 1815 ± 139 nmol/min/mg for the preparations generated (n = 4)
in this investigation. These values are in agreement with previously published values [21]
and represent a 4.3-fold stimulation by nicardipine. Both Aβ peptide isoforms were also
able to elicit a stimulation in the ATPase activity of purified, reconstituted P-gp as shown in
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Figure 1e. The estimated maximal degree of stimulation by Aβ40 was 1.5-fold, potentially
suggesting that it is a relatively weak substrate of P-gp. Aβ42 produced a comparatively
greater stimulation of approximately 2.2-fold, which is equivalent, or greater, than estab-
lished substrates vinblastine, paclitaxel, and rhodamine 123 [19]. It was not possible to
generate a more extensive range of concentrations for the peptides (see Methods Section
5.5) and consequently, the affinity cannot be reliably estimated.
Overall, the two assays provide further evidence that Aβ40 and Aβ42 interact with
P-gp and the use of purified, reconstituted protein demonstrates a direct mechanism.
In addition, the nature of the effect on ATP hydrolysis may indicate their interaction is akin
to a transported substrate, for which there is considerable evidence using cellular systems
(for review see [16]).
2.2. P-gp Mediates Aβ42 Transport from Brain to Capillary Lumen Ex Vivo
Freshly isolated brain capillaries provide a unique ex vivo model of the BBB, which can
be used to study endogenous transport processes across the endothelium. P-gp is expressed
on the luminal (blood-facing) membrane of the BBB, where it exports substrates from the
endothelial cells into the blood [33].
To provide a physiological perspective to the binding and transport assays studied in
Section 2.1, we compared the accumulation of fluorescent labelled human Aβ42 (HiLyteTM-
hAβ42; 5 µM) at steady state in brain capillaries isolated from wild-type (WT) versus
P-gp-knockout (KO) mice, using confocal microscopy combined with quantitative image
analysis. The Aβ42 isoform was selected as it displayed a greater capacity for stimulating
ATP-hydrolysis and therefore was deemed a higher affinity substrate of P-gp than Aβ40
(Figure 1e). Accumulation of HiLyteTM-hAβ42 was lower in the lumen of capillaries isolated
from P-gp KO mice compared to capillaries isolated from WT mice (Figure 2a,b). Image
analysis revealed that luminal HiLyteTM-hAβ42 fluorescence was significantly (p < 0.001)
reduced in capillaries from P-gp KO (60.1 ± 4.4 (r.f.u.)) versus WT mice (127.8 ± 5.9 (r.f.u.)),
indicating that P-gp is necessary for active Aβ transport from the bath to the vascular space.
In concordance, luminal HiLyteTM-hAβ42 fluorescence was significantly (p < 0.001) reduced
in WT capillaries treated with the P-gp-specific inhibitor PSC833 (51.9 ± 2.4 (r.f.u.)) versus
untreated capillaries (127.8 ± 5.9 (r.f.u.)), whereas fluorescence levels remained comparable
between treated (60.1 ± 4.4 (r.f.u.)) versus untreated KO capillaries (55.5 ± 3.9 (r.f.u.))
(Figure 2c). The residual fluorescence present in PSC833-treated capillaries is due to non-
specific binding of the HiLyteTM-hAβ42 primarily to the endothelial cell surface. Figure 2c
shows specific luminal NBD-CSA fluorescence that was taken as the difference between
total luminal fluorescence and fluorescence in the presence of PSC833, which represents
the P-gp-specific component of HiLyteTM-hAβ42 transport. Together, these data indicate
that the observed differences in fluorescence accumulation are specific to P-gp-mediated
transport. Western immunoblot analysis confirmed high P-gp protein expression in capil-
lary membranes from WT mice and lack of P-gp expression in capillary membranes from
P-gp KO mice. In contrast, low-density lipoprotein receptor-related protein 1 (LRP-1),
the receptor at the abluminal (brain-facing) membrane of the capillaries responsible for Aβ
uptake into the endothelial cells, was detected in capillaries from both WT and P-gp KO
mice (Figure 2d).
These results confirm our previous findings showing Aβ transport at the BBB is an
active and ATP-dependent two-step process, involving LRP-1-mediated Aβ uptake from
the brain into capillary endothelial cells, followed by P-gp-mediated Aβ transport from the
endothelium into the capillary lumen [18,34].
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Figure 2. P-gp-mediated human Aβ42 (hAβ42) transport in isolated brain capillaries. (a), (b) Representative confocal images
sho ing accu ulation of HiLyteTM-hAβ42 in capillary lumens isolated from wild-type (WT) mice, but not in capillaries
from P-gp knockout (KO) mice after a 1-h incubation (ste dy state; 5 µM HiLyteTM-hAβ42). (c) Data after di ital image
analysis using ImageJ. Specific fluorescence refers to the differ ce betwee total luminal HiLyteTM-hAβ42 fluorescence
and HiLyteTM-hAβ42 fluoresce ce in t e presence of the P-gp-specific inhibitor PSC833 (5 µM). (d) Western blot showing
P-gp protein expression in isolated capillaries from WT mice, but not in capillaries isolated from P-gp KO mice. In contrast,
LRP-1 is expressed in isolated capillaries from both WT mice and P-gp KO mice. β-actin was used as the loading control.
Statistics: data per group are given as mean ± SEM for 10 capillaries from one preparation (pooled tissue: WT (n = 10 mice),
P-gp KO (n = 10 mice)). Shown are relative fluorescence units ((r.f.u.) scale 0–255). *** Significantly lower than control,
p < 0.001.
2.3. P-gp Protein Is Expresse in Human Neuroblastoma Cells
Expression of P-gp protein in neurons has been a point of contention. For example,
several groups have demonstrated P-gp expression in neuronally-derived cell lines [35–38]
and on peripheral nerve tissue at the blood-nerve-barrier (BNB) [39–41], whereas others
have failed to do so or have demonstrated t t it is only expressed in the context of brain
inju y or pathology [42–47].
We analysed P-gp protein expression by W st rn blot in cell lysates obtain d from
three separate human neuroblasto a cell lines that are regularly use in brain and AD-
related research.
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Figure 3 (left panel) shows that P-gp could be detected in Be(2)C, SH-SY-5Y and SK-N-
SH cells, at levels comparable to those found in human brain endothelial hCMEC/D3 cells,
which are commonly used as an in vitro BBB endothelial cell model.
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2.4. P-gp Is Active and Can Be Chemically Inhibited in CHO-APP and SK-N-SH Cells
Calcein-AM is a soluble hydrophobic non-fluorescent dye that rapidly crosses the
plasma membrane and is actively exported by P-gp. When P-gp is active, calcein-AM
is efficiently removed from the cell before it can undergo hydrolysis. If P-gp is inactive,
intracellular esterases cleave calcein-AM to produce the free acid calcein, which cannot be
transported by P-gp and thus remains trapped inside the cell where it produces an intense
fluorescence [48]. Therefore, measuring the accumulation of fluorescent calcein is a rapid
and sensitive method for studying P-gp activity.
Experiments were firstly performed in the CHO-APP cells, which secrete relatively
large quantities of Aβ peptides. P-gp protein was confirmed to be expressed in CHO-APP
cells at a level consistent with that of the parental CHO-K1 cell line (Figure 3; right panel).
Verapamil and nicardipine, both anti-hypertensive calcium channel blockers, were selected
due to their well established and strong P-gp inhibitory activity [49,50]. Figure 4a,b show
that addition of these P-gp inhibitors to CHO-APP cells increased fluorescence, indicat-
ing increased intracellular calcein accumulation, in a concentration-dependent manner.
Experiments were subsequently replicated in SK-N-SH neuroblastoma cells, which have
previously been established to secrete Aβ40 and Aβ42 peptides [51,52]. Data show a similar
concentration-dependent effect of P-gp inhibition on intracellular fluorescence (Figure 4c,d).
Together, these data indicate that P-gp is active and can be chemically inhibited by these
two drugs in both cell lines. Furthermore, nicardipine was approximately three-fold more
effective than verapamil at inhibiting P-gp-mediated export of calcein-AM (Figure 4),
which corresponds with previously published findings [49,50].
Although calcein-AM is a substrate of both P-gp and the related multi-drug resistance
transporter ABCC1/MRP1, verapamil and nicardipine do not directly affect ABCC1/MRP1 ac-
tivity [53,54]. Furthermore, verapamil does not appear to affect the activity of other trans-
porters including ABCG2/BCRP, ABCG4, LRP-1, or RAGE that have been implicated in
Aβ transport [55–58]. Although nicardipine is an effective inhibitor of ABCG2/BCRP [59],
expression of this transport protein has not been reported in SK-N-SH and is absent or
minimal CHO cells [60–62]. Therefore, the observations described in Figure 4 are deemed
to be specific to P-gp and not confounded by activity of other ABC transporters.
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2.5. Cell viability Assays
Reduced cell viability compro ises the production and secretion of cellular prod-
ucts. Therefore, MTT assays were performed to verify whether incubation with the P-gp
inhibitors verapamil and nicardipine at the final exp rimental concentrations (1–30 µM),
would affect CHO-APP o SK-N-SH cell viability. Figure 5a shows that CHO-APP cell
vi bility was not affected by the in ibitors. There was a margi al effect of high verapamil
concentrations on SK-N-SH cell via ility. However, this was not statistically significant
(p > 0.05 compared to control) (Figure 5b).
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2.6. Inhibition of P-gp Reduces Aβ Secretion from CHO-APP and SK-N-SH Cells
To investigate whether P-gp is involved in the export of Aβ, we assessed the effect
of chemical inhibition of P-gp activity on the secretion of Aβ40 and Aβ42 peptides into
cell media. Initial experiments were conducted using CHO-APP cells, which overexpress
human APP and exhibit ample P-gp expression. Considering these cells produce large
quantities of Aβ, we were able to use in-house ELISAs to quantify these peptides in the
supernatant. Control (untreated) cells in our experiments secreted on average 3.3 and
1.1 ng/mL Aβ40 and Aβ42, respectively. Treatment of CHO-APP with verapamil for 24 h
significantly reduced secretion of Aβ40 (Figure 6a) and Aβ42 (Figure 6b) into the media
compared to control in a concentration-dependent manner. Results were most pronounced
with verapamil 30 µM, which reduced Aβ40 and Aβ42 secretion by approximately half,
compared to control. Treatment with nicardipine similarly yielded a dose-dependent
effect on Aβ40 secretion, with 10 µM reducing Aβ40 levels to 48 ± 7.6% of that of control
(Figure 6a); reductions in Aβ42 levels were also significant. However, a dose-dependent
relationship could not be confirmed due to variability in response to the highest nicardipine
concentration (Figure 6b).
Our observations in CHO-APP are in line with findings from other groups that
also report the involvement of P-gp in Aβ export in vitro, utilising human embryonic
HEK293 cells transfected with APP695 [26], P-gp-transfected Lewis lung carcinoma cells [63]
and LS-180 human colon adenocarcinoma cells [64]. However, the relationship between
P-gp and Aβ has, until now, not been investigated in neurons where these peptides are
predominantly generated. Therefore, we applied the same experimental conditions to
SK-N-SH human neuroblastoma cells.
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Since SK-N-SH cells secrete considerably smaller quantities of peptides (approximately
100-fold less than CHO-APP cells), the cell supernatants were analysed using commercial
ELISA kits. Control SK-N-SH cells were found to secrete on average 29.0 pg/mL Aβ40
and 3.6 pg/mL Aβ42. As seen in Figure 6c, pharmacological inhibition of P-gp signifi-
cantly and dose-dependently reduced Aβ40 secretion from SK-N-SH cells. Results were
most pronounced with verapamil 30 µM and nicardipine 10 µM, which reduced levels
to 42 ± 6.1% and 43 ± 4.0% of that of control, respectively. Verapamil similarly yielded
a dose-d pendent reduction in Aβ42 ecretion (Figur 6d). I ter stingly, the same obser-
vation as seen in CHO-APP (Figure 6b) was also obs ved in SK-N-SH, with the higher
nicardipine concentration producing an unexpected i crea in Aβ42. Verapamil has been
shown not to affect cellular Aβ40 or Aβ42 production [65], suggest ng that the observed
reductio s in Aβ secr tion can b attributable to duced P-gp-mediated export. As antici-
pated, SK-N-SH cells consistently secreted higher proportions of Aβ40 compared to Aβ42
(approximately 8:1 ratio), which corresponds wi h previously reported in vitro ata s well
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as physiological ratios observed in human AD brains [52,66]. Overall, chemical inhibition
using P-gp-specific inhibitors was demonstrated to suppress Aβ peptide secretion from
both CHO-APP and SK-N-SH cells.
3. Discussion
Positive correlations between P-gp and Aβ transport have previously been described
in human and animal studies [16]. However, data from in vitro studies have been more con-
flicting. The P-gp/Aβ interaction was first proposed by Lam et al., who used a combination
of pharmacological inhibition, binding studies, and vesicular transport assays to establish
P-gp as an Aβ exporter [26]. Since then, whilst this relationship has been reinforced in
several cell models, other groups have reported contradicting data suggesting that P-gp
modulation does not affect Aβ transport [16]. In the present study, three lines of evidence
collectively point to the involvement of P-gp in the export of Aβ40 and Aβ42 peptides.
Firstly, binding assays utilising purified, reconstituted P-gp demonstrate a direct interac-
tion. Whilst this finding is in line with that reported by Lam et al. [26], the use of intrinsic
tryptophan quenching as described here, over quenching of a covalently attached fluo-
rophore probe, has the advantage of stipulating a more direct transporter-peptide binding
interaction. Concertedly, Aβ was able to stimulate ATP hydrolysis in a manner comparable
with other established P-gp substrates. Secondly, vessels from the P-gp-knockout mice
model provided firm physiological evidence for P-gp-mediated transport of the Aβ42
peptide at the BBB endothelium. Thirdly, in distinction from previously published in vitro
studies that have utilised exogenously applied Aβ peptides [17,26,63,67], our findings
from two distinct cell lines (non-neuronal CHO-APP and human neuron-like SK-N-SH)
demonstrate that endogenously generated Aβ peptides are transported by endogenously
expressed P-gp.
Interestingly, not only do our data indicate that P-gp is expressed and active in neu-
ronal cells, they also show that the extent of inhibition of Aβ efflux by P-gp in SK-N-SH
neuroblastoma cells was comparably significant to that in CHO-APP cells. This highlights a
previously unappreciated role of P-gp in neurons that not only reshapes our understanding
of Aβ pathology, but also has potentially significant implications for drug development
and drug-drug interactions. Further studies utilising primary neurons and in vivo mod-
els are warranted to confirm the clinical significance of these effects. Notably, although
Aβ secretion from both CHO-APP and SK-N-SH cells were significantly reduced in the
presence of P-gp inhibitors (Figure 6), secretion was not completely eliminated. This is
consistent with previously reported in vitro data [26,63]. This may be attributed to several
factors, including those pertaining to the drugs themselves, such as concentration, half-life,
and efficacy of inhibition, as well as the involvement of auxiliary peptide export mecha-
nisms such as exosomes and other active transport proteins [55,68,69]. In fact, incomplete
elimination of cellular Aβ may be favourable in the context of therapeutic applications [70].
Several reports regard APP and Aβ peptides as serving important physiological roles,
including maintaining neuronal function, facilitating brain development, and conferring
protection against pathogens [70,71]. Rather, P-gp activity could be a potential target for
the development of novel therapeutics in AD to limit the neurotoxic effects of excess Aβ
in the brain [64,72,73]. One approach would be to upregulate P-gp function to enhance
Aβ export; at the neuron, this could remove intracellularly accumulated peptides, and at
the BBB, extracellularly deposited peptides could be cleared. It has been established that
intraneuronal Aβ accumulation may be just as toxic, and precedes, extracellular accumu-
lation [10,11]. Hence, alleviating the Aβ load within neurons by facilitating the clearance
process out of these cells would be potentially beneficial. However, there is growing
evidence that the cell-to-cell spread of misfolded and aggregated proteins, including Aβ
peptides, tau proteins and α-synuclein contributes to disease progression in AD as well
as other neurodegenerative conditions [74–77]. In particular, Aβ peptides have been re-
ported to behave as “seeds” that spread in the brain in a prion-like manner [78]. Therefore,
further research is necessary to ensure that any transient intermediary extracellular accu-
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mulation resulting from increased neuronal secretion of Aβ peptides does not lead to an
increase in “seeding” events. In addition, further clarification is required to determine what
happens to these peptides once they are exported from their cells of origin. Although not
fully elucidated, association with the lipid carrier apolipoprotein E is known to be an
important step in the peptide clearance process [79,80]. Critically, any therapeutics aimed
at upregulating P-gp function have the potential for drug-drug interactions or off-target
effects in patients with comorbidities (such as multi-drug resistant cancers) that must
be considered. An alternate recommendation would be to reconsider the prescribing of
medications with P-gp-inhibitory effects in patients who are at risk of developing, or have
been diagnosed with AD.
As previously mentioned, P-gp expression has been reported in neurons in the periph-
ery at the BNB. It has been suggested that increased permeability and breakdown of the
BNB is a contributor to immune- and inflammatory-related neuropathic and neurodegen-
erative disorders [39,81]. Although expression of P-gp at the BNB has been indicated by
several studies to be significantly lower than expression at the BBB [40,41], further studies
are needed to determine whether P-gp serves a protective function in these neurons and
whether modulation of activity may be beneficial in the prevention of other neurodegener-
ative disorders.
Lastly, it has been reported that P-gp function declines with ageing, and moreover,
Aβ peptides themselves may directly compromise P-gp expression and activity [82–85].
These factors potentially propagate a vicious cycle that drives AD progression. Therefore,
it is imperative to unravel the underlying mechanisms that lead to the decay of P-gp
function in the ageing process. So far, post-translational mechanisms such as protein
ubiquitination have been described [72,86], which could explain why P-gp expression
at the gene level has not yet been identified as a strong genetic risk factor for AD de-
velopment [87,88]. Further studies are warranted to establish whether curtailing age-
and/or disease-related P-gp decline would effectuate any symptomatic improvements or
disease-modifying effects.
4. Conclusions
The hydrophobic and membrane-anchored nature of the intraneuronally-generated
Aβ peptide suggests that simple diffusion, as it has until now been assumed, does not
adequately explain the mechanism of its expulsion into the extracellular space. Data pre-
sented here provide compelling evidence to substantiate the ability for P-gp to export Aβ.
This not only occurs at the BBB endothelium, but for the first time, we have shown that
the clearance of Aβ out of neurons is also an active process mediated by P-gp. Further
studies are still needed to examine whether modulating P-gp function affects markers of
neurodegeneration in vivo, and to confirm if this is a viable avenue to pursue in the search
for effective AD therapies. Nonetheless, clarifying the molecular mechanisms involved in
the pathway of the Aβ peptide, from its synthesis in the cell to clearance from the brain,
is critical for our understanding of the pathophysiology of AD.
5. Materials and Methods
5.1. Materials
All cell culture materials including media and additives were purchased from Thermo
Fisher Scientific (Scoresby, VIC, Australia), except for Hanks’ Balanced Salt Solution (HBSS)
which was purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).
For P-gp purification and reconstitution steps (Section 5.3), dodecyl-β-D-maltoside
was obtained from Anatrace (Ohio, USA), Ni-NTA His-Bind resin from Merck (Bayswater,
VIC, Australia), and SM2 BioBeads from BioRad (Gladesville, NSW, Australia).
Reagents for casting SDS-PAGE gels including Tris-HCl, sodium dodecyl sulfate
(SDS) and tetramethylethylenediamine (TEMED) were purchased from VWR Life Science
(Tingalpa, QLD, Australia). 40% acrylamide/bis-acrylamide solution was from BioRad
(Gladesville, NSW, Australia). Ammonium persulfate was from Sigma-Aldrich. Nitrocellu-
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lose membranes and enhanced chemiluminescent reagents were purchased from Merck,
GE Healthcare and Pierce (Rockford, IL, USA). The Pierce Bicinchoninic acid (BCA) protein
assay kit was purchased from Thermo Fisher Scientific.
(±)-Verapamil hydrochloride and nicardipine hydrochloride were obtained from
Sigma-Aldrich. Stock solutions were prepared at 25 µM by dissolving the powders in
dimethylsulfoxide (DMSO) and stored at −20 ◦C. Calcein acetoxymethyl ester (calcein-
AM), also obtained from Sigma-Aldrich, was diluted in DMSO to produce a 4 µM stock
solution and stored at −20 ◦C.
Lypholised human Aβ 1-40 (Aβ40) and Aβ 1-42 (Aβ42) peptides, and HiLyteTM-hAβ42
were purchased from AnaSpec (Fremont, CA, USA).
Chemicals for brain capillary isolation (Section 5.7) were purchased from Sigma-
Aldrich (St Louis, MO, USA). All other reagents, unless otherwise specified, including
bovine serum albumin (BSA), IGEPAL, protease inhibitor cocktail, copper (II) sulfate
pentahydrate, thiazolyl blue tetrazoliumbromide (MTT) powder, DMSO, glycine, Instant
BlueTM protein stain, phosphate buffered saline (PBS), sodium carbonate, sodium bicarbon-
ate, sodium hydroxide, sulfuric acid, and Tetramethylbenzidine (TMB) Liquid Substrate
System were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia).
5.2. Antibodies
Anti-ABCB1 monoclonal C219 antibodies were obtained from Novus Biologicals
and Abcam (Cambridge, MA, USA). Anti-LRP-1 antibody was obtained from Calbiochem-
Novabiochem (La Jolla, CA, USA). Anti-β-actin antibody was purchased from Abcam. Anti-
α-tubulin monoclonal antibody, and secondary HRP-conjugated anti-mouse and anti-rabbit
antibodies were purchased from Sigma-Aldrich. For the in-house Aβ40 ELISA, capture
and detection antibodies were anti-Aβ1-40 (polyclonal rabbit; catalog no. ABN240 from
Merck Millipore) and anti-Aβ1-16 (monoclonal mouse; clone AB10 from Sigma-Aldrich),
respectively. For the in-house Aβ42 ELISA, capture and detection antibodies were anti-
Aβ1-16 and anti-Aβ37-42 (polyclonal rabbit; catalog no. Ab34376 from Abcam), respectively.
5.3. Purification and Reconstitution of P-gp
A C-terminal dodecyl-histidine version of human P-gp was expressed in Trichoplusia
ni (High-Five) insect cells using recombinant baculovirus as previously described [19]. Fol-
lowing expression, crude membranes were prepared using differential ultra-centrifugation
and stored at −80 ◦C. P-gp was extracted from the High-Five crude membranes using the
detergent dodecyl-β-D-maltoside (DDM) and purified by metal affinity chromatography
on Ni-NTA His-Bind resin. Chromatography buffers contained 0.1% (w/v) DDM and were
supplemented with 0.1% (w/v) of a lipid mixture comprising a 4:1 ratio of E. coli total
lipid extract and cholesterol. This enabled rapid reconstitution into vesicles by detergent
adsorption using SM2 BioBeads.
5.4. Tryptophan Fluorescence Quenching Assay for Ligand Binding to Purified, Reconstituted P-gp
Binding of Aβ peptides to purified, reconstituted P-gp was measured by quenching
of the intrinsic fluorescence of endogenous tryptophan residues as described [23] and
modified [19]. However, imidazole was removed by ultra-centrifugation (70,000 g, 20 min
4 ◦C) of reconstituted P-gp and subsequent resuspension in binding buffer (20 mM MOPS,
pH 8.0, 200 mM NaCl). P-gp (10–15 µg) was added to quartz silica cuvettes in a total volume
of 300 µL. A tryptophan fluorescence emission spectrum was measured from 300–400 nm
(emission slit width 5 nm) using excitation at 295 ± 10 nm at a scan speed of 120 nm/min.
Lyophilised Aβ40 and Aβ42 peptides were resuspended in 2 mM NaOH at pH~10.5 to
concentrations of 1.6 mg/mL (385 mM) and 1.0 mg/mL (221 mM) as described [89].
The peptides were added to sample cuvettes at concentrations in the range of 1–25 µM
(Aβ42) or 1–50 µM (Aβ40). Sample cuvettes were held at a temperature of 37 ◦C and
incubated for 20 min prior to measuring the fluorescence emission spectrum. Nicardipine
(5 µM) was added following the final Aβ peptide addition to determine the maximal
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possible quenching. The spectra obtained in the presence of nicardipine were subtracted
from those containing Aβ peptide to remove background signal.
5.5. ATP Hydrolysis by Purified, Reconstituted P-gp
The rate of ATP hydrolysis by purified, reconstituted P-gp was determined spec-
trophotometrically by the liberation of inorganic phosphate as described [19,90]. Samples
of P-gp (0.2–0.5 µg) were incubated in 96-well microplates with disodium-ATP (2 mM)
and either Aβ peptide (1–50 µM) or nicardipine (10−9 − 3 × 10−4 M) in a total volume
of 50 µL at 37 ◦C for 40 min. The absorbance (λ = 750 nm) was measured using an iMark
plate reader. The activity values were normalised to the basal (i.e., substrate-free) level
and plotted as a function of ligand concentration. Data in the presence of nicardipine were
analysed using the general dose-response curve:
v = vinitial +
(
v f inal − vinitial
)
/
(
1 + 10log (EC50−[L])
)
as described in [19], where: v is the activity, L is the compound added and EC50 is the
potency of effect. Complete dose-response curves were not possible for the Aβ peptides
due to poor solubility and their expense from commercial suppliers.
5.6. Animals
Animal experiments were approved by the Institutional Animal Care and Use Com-
mittee of the University of Kentucky (protocol no.: 2014–1233, PI: Hartz; approved April,
2014) and were carried out in accordance with AAALAC regulations, the US Department
of Agriculture Animal Welfare Act, and the Guide for the Care and Use of Laboratory
Animals of the NIH.
Male P-gp knockout (KO) mice (CF-1 strain; CF1-Abcb1amds—PGP) and correspond-
ing male CF-1 wild-type (WT) mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). Mice were 9 weeks old with an average body weight of 33.7 g
(31–35 g) for WT mice and 36.3 g (33–42 g) for P-gp KO mice. All mice were single-housed
and kept under controlled environmental conditions (21 ◦C; 51–62% relative humidity;
12-h light/dark cycle) using an Ecoflo Allentown ventilation system (Allentown Inc., Al-
lentown, NJ, USA). Animals were monitored at least once a day and had free access to tap
water and Harlan Teklad Chow 2918 rodent feed (Harlan Laboratories Inc., Indianapolis,
IN, USA). After shipping, animals were allowed to acclimate to their new environment for
at least 7 days prior to experiments.
5.7. Brain Capillary Isolation
Brain capillaries were isolated as previously described [18,72,86]. Mice were eu-
thanised by CO2 inhalation and decapitated, brains were removed, dissected, and ho-
mogenised in cold PBS buffer (2.7 mM KCl, 1.46 mM KH2PO4, 136.9 mM NaCl, 8.1 mM
Na2HPO4, 5 mM D-glucose, 1 mM sodium pyruvate, pH 7.4). Ficoll® was added to the
brain homogenate to a final concentration of 15% and the Ficoll®/brain mixture was cen-
trifuged at 5800× g for 15 min at 4 ◦C. After resuspending the pellet in 1% BSA/PBS,
the capillary suspension was passed over a glass bead column to purify capillaries from
debris and red blood cells. Capillaries adhering to the glass beads were collected by gentle
agitation in 1% BSA/PBS, washed with BSA-free PBS and used for experiments.
5.8. Aβ Transport Assay in Isolated Brain Capillaries
To determine P-gp-mediated transport of Aβ, freshly isolated brain capillaries from
WT and P-gp KO mice were incubated for 1 h at room temperature with HiLyte™-hAβ42
(5 µM; [18,72,86]). For each group, images of 10 capillaries were acquired by confocal
microscopy (Zeiss LSM 710 inverted confocal microscope, 40× 1.2 NA water immersion
objective, 488 nm line of argon laser, Carl Zeiss Inc., Thornwood, NY, USA). Images were
analysed by quantitating luminal HiLyte™-hAβ42 fluorescence using ImageJ software
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v1.48. Specific, luminal HiLyte™-hAβ42 fluorescence was taken as the difference between
total luminal fluorescence and fluorescence in the presence of the P-gp-specific inhibitor
PSC833 (5 µM; [18,72,86]).
5.9. Brain Capillary Harvest and Western Blot Analysis
Protein expression levels in brain capillaries were analysed by Western blotting as
previously described [18,72,86]. Brain capillaries were homogenised in lysis buffer (Sigma-
Aldrich, St Louis, MO, USA) containing Complete® protease inhibitor (Roche, Mannheim,
Germany). Homogenised samples were centrifuged at 100,000× g for 90 min. Brain capillary
membranes were resuspended in buffer containing protease inhibitor and stored at −80 ◦C.
Western blots were performed using the Invitrogen NuPageTM Bis-Tris electrophoresis
and blotting system (Invitrogen, Carlsbad, CA, USA). After electrophoresis and protein
transfer, membranes were blocked and incubated overnight with the primary antibody
as indicated (P-gp (Abcam): 1:100 (1 µg/mL); β-actin: 1:1000 (1 µg/mL); LRP-1: 1:750
(1 µg/mL)). Membranes were washed and incubated for 1 h with horseradish peroxidase-
conjugated ImmunoPure® secondary IgG (1:10,000; Pierce, Rockford, IL, USA). Proteins
bands were detected via enhanced chemiluminescence and recorded using a BioRad Gel
Doc 2000TM gel documentation system (BioRad, Hercules, CA, USA).
5.10. Cell Culture
Chinese hamster ovary cells stably overexpressing human APP (CHO-APP) were
a generous gift from Dr. Woojin Kim (Faculty of Medicine and Health, University of
Sydney, Sydney, Australia). The cells were generated by transfecting CHO cells with
recombinant vectors expressing human 695-amino acid APP cDNA and a puromycin
resistance gene, as described [91]. Cells were routinely maintained in F-12 growth medium
supplemented with heat-inactivated foetal bovine serum (FBS; 10% v/v), L-glutamine
(2 mM), penicillin (100 units/mL) and streptomycin (100 µg/mL), with the addition of
puromycin (7.5 µg/mL), at 37 ◦C in humidified air containing 5% CO2.
SK-N-SH human neuroblastoma cells were obtained from Sigma-Aldrich (Castle
Hill, NSW, Australia) and maintained in MEM growth medium supplemented with heat-
inactivated FBS (10% v/v), L-glutamine (2 mM), penicillin (100 units/mL) and streptomycin
(100 µg/mL) at 37 ◦C in 5% CO2.
5.11. Cell Harvest and Western Blot Analysis
Cells were washed twice with ice-cold PBS and lysed with cell lysis buffer containing
5 µL/mL protease inhibitor cocktail in IGEPAL. Lysates were syringed with 23-gauge
needles to shear cellular DNA and centrifuged at 12,000× g rpm at 4 ◦C for 5 min. Total
cell protein concentrations of the resulting supernatants were determined using BCA
protein assays. Equal amounts of cell protein were loaded onto 10% (v/v) acrylamide gels
for separation by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes,
blocked for 1 h using 5% (w/v) skim milk or 0.1% (w/v) BSA in PBS-Tween (0.05% v/v),
then incubated with anti-ABCB1 (1:2000 (Novus Biologicals), overnight 4 ◦C) or anti-
tubulin (1:3000, overnight 4 ◦C) antibodies. Membranes were rinsed with PBS-Tween,
then incubated with HRP-conjugated anti-mouse secondary antibodies (1:10,000) for 1 h at
room temperature, and then rinsed again with PBS-Tween. Protein bands were visualised
via chemiluminescence and the Bio-Rad ChemiDoc imaging system.
5.12. Calcein-AM Assay
P-glycoprotein activity was measured using the calcein-AM assay. CHO-APP and SK-
N-SH cells were seeded into 96-well clear-bottom black-walled plates at 4 × 104 cells/well
in full culture medium and incubated overnight. The next day when cells reached ~80–90%
confluency, media was discarded, and the cells were washed with phenol red-free HBSS
or MEM. To assess the inhibitory effect of verapamil and nicardipine on P-gp activity,
the inhibitors and DMSO control were prepared at 2× concentrations in HBSS buffer and
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added to the cells at 100 µL/well. Calcein-AM substrate was also prepared at 2× concen-
tration, and 100 µL was added to each well using a multi-channel pipette to achieve the
final working concentrations. Fluorescence measurements were obtained every minute for
20 min, starting immediately after addition of calcein-AM, using the Perkin Elmer Victor
X plate reader. The excitation and emission wavelengths were set at 485 and 535 nm, re-
spectively. Temperature was maintained at 37 ◦C. Measurements were recorded in relative
fluorescence units (RFU) and computed using Graphpad Prism software.
5.13. MTT Assay
Cells were seeded into a 96-well plate in full culture medium and allowed to adhere
overnight. The next day, media was discarded, and cells were incubated with 200 µL/well of
verapamil (1–30 µM), nicardipine (1–10 µM), DMSO (1:1000), or no treatment in full culture
medium for 24 h. On the day of the experiment, the cells were washed with serum-free medium,
to minimise background effect caused by presence of serum. 10X MTT stock (5 mg/mL, pre-
pared in PBS and filter sterilised using a 0.22 µm syringe filter unit) was diluted to 0.5 mg/mL
using serum-free medium to yield the working concentration. Using a multi-channel pipette,
100 µL of 1× MTT reagent was added to each well. Cells were incubated for two hours at
37 ◦C, washed with PBS, then lysed with 100 µL/well of DMSO. The plate was wrapped in foil
and placed on a shaker for approximately 10 min to allow even distribution of colour across
the wells. Absorbance was measured at 550 nm using a Bio-Rad Microplate Reader.
5.14. Preparation of Aβ Peptides
Aβ40 and Aβ42 solutions were prepared by dissolving lyophilised peptides in 2 mM
NaOH (pH~10.5). By avoiding the isoelectric point of Aβ (5.5) in the initial solvation
step, aggregation and oligomerisation of the peptide is minimised [89]. For fluorescence
quenching assays, Aβ40 and Aβ42 peptides were prepared fresh at 385 mM and 221 mM, re-
spectively. For ELISA standards, Aβ40 and Aβ42 2× solutions were prepared and stored at
−80 ◦C in single-use aliquots. These stock solutions were diluted in PBS (1:1) immediately
prior to use to readjust the pH from 10.5 to physiological 7.4.
5.15. Enzyme-Linked Immunosorbent Assay (ELISA)
CHO-APP and SK-N-SH cells were seeded onto 24-well plates. The following day,
cells were treated with 400 µL/well verapamil, nicardipine, DMSO or plain cell culture
media. Because SK-N-SH cells have been reported to secrete low concentrations of Aβ
peptides (in the picogram/mL range) [51,52,92,93], an experiment period of 24 h was
selected to allow time to accumulate sufficient peptide in the cell supernatant for detection
using ELISA. After 24 h, media from each well was collected, treated with 1 µL protease
inhibitor cocktail (equivalent to 0.25 mM AEBSF), centrifuged at 3000× g RPM at 4 ◦C for
5 min to remove debris, and used immediately for ELISA (to avoid peptide degradation
due to storage and freeze/thawing). Cellular secretion of Aβ40 and Aβ42 into media was
detected and quantified by sandwich ELISA.
For CHO-APP supernatant, a pair of in-house isoform-specific ELISAs were devel-
oped: analyses were performed in 96-well Nunc-ImmunoTM MaxiSorp plates (Thermo
Fisher Scientific) coated with 100 µL per well of capture antibody at 2.5 µg/mL in 0.1 M
carbonate buffer (pH 9.5) at 4 ◦C overnight. Wells were washed four times with PBS-Tween
(0.05% v/v) to remove any unbound antibody, before blocking with 200 µL of blocking
buffer (2% BSA, 7.5 g/L glycine in PBS) for 1 h at room temperature. After another four
washes, 100 µL peptide standards and samples were loaded into the wells and incubated
for 1 h at room temperature on a slow-speed shaker. Washing was repeated, then wells
were incubated with 100 µL of the appropriate primary detection antibody (1:1000 in 1%
BSA, 3.75 g/L glycine in PBS) for 1 h at room temperature. After washing, 100 µL of sec-
ondary horseradish peroxidase-conjugated antibody (1:10,000 in 1% BSA, 3.75 g/L glycine
in PBS) was added, and the plate was incubated for 1 h at room temperature. Following
another four washes, 100 µL of TMB was added to each well. Plates were incubated in the
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dark for 30 min at room temperature, then the reaction was terminated by the addition of
50 µL of H2SO4 (20% v/v). Absorbance values at 450 nm were measured using a Bio-Rad
Microplate Reader. Assay sensitivity was <300 pg/mL for both Aβ40 and Aβ42.
For SK-N-SH supernatant, the commercial human Aβ40 and Aβ42 ELISA kits (Invitro-
gen, catalogue no. KHB3481 and KHB3544) were used in accordance with the manufac-
turer’s protocols.
Data were computed using Graphpad Prism software; a non-linear 4-parameter
regression was used to generate a standard curve, from which the unknown concentrations
were determined. ELISA data were adjusted for total protein content of each sample
(as determined by BCA protein assays) to account for any potential slight variations
in cell viability, by multiplying the ELISA concentration by the ratio of control protein
concentration to sample protein concentration.
5.16. Statistical Analysis
Data were analysed using Graphpad Prism (v6.01, La Jolla, CA, USA) and Microsoft
Excel 2019. Values are expressed as mean ± SEM. MTT and ELISA data were statistically
analysed using one-way ANOVA followed by Dunnett’s test. Two-tailed unpaired Stu-
dent’s t test was used to evaluate differences between WT and P-gp KO mice. A p value of
0.05 was considered significant (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).
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